- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Keenova Therapeutics to Report Q4 2025 Results on March 31, 2026
Leading global developer of branded therapeutics to host conference call on earnings release date.
Mar. 16, 2026 at 4:00pm
Got story updates? Submit your updates here. ›
Keenova Therapeutics, a leading global developer and manufacturer of branded therapeutics, announced that it will report its fourth-quarter 2025 financial results on Tuesday, March 31, 2026, before market open. The company will host a conference call on the same day at 8:00 a.m. ET.
Why it matters
Keenova Therapeutics is a major player in the pharmaceutical industry, focused on developing treatments for rare and underserved conditions. The company's quarterly earnings reports provide insight into its financial performance and product pipeline, which is of interest to investors, analysts, and the broader healthcare community.
The details
Keenova will report its Q4 2025 results and host a conference call to discuss the findings. The audio webcast of the call will be available on the company's investor relations website. Participants can also access the call through a conference line after registering for a personalized dial-in number and PIN.
- Keenova Therapeutics will report Q4 2025 financial results on Tuesday, March 31, 2026.
- The company will host a conference call on the same day at 8:00 a.m. ET.
The players
Keenova Therapeutics
A leading global developer and manufacturer of branded therapeutics that strives to help patients with rare or unaddressed conditions live happier and healthier lives.
What’s next
Investors and analysts will be closely watching Keenova's Q4 2025 earnings report and conference call for updates on the company's financial performance, product pipeline, and strategic direction.
The takeaway
As a major player in the pharmaceutical industry, Keenova Therapeutics' quarterly earnings reports provide valuable insights into the company's financial health and its efforts to develop treatments for rare and underserved medical conditions.
